Jpmorgan Chase & CO Kura Oncology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 365,921 shares of KURA stock, worth $3.02 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
365,921
Previous 409,241
10.59%
Holding current value
$3.02 Million
Previous $8 Million
60.14%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding KURA
# of Institutions
193Shares Held
77.5MCall Options Held
103KPut Options Held
106K-
Black Rock Inc. New York, NY6.97MShares$57.5 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.8MShares$47.9 Million0.71% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.08MShares$41.9 Million1.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.82MShares$39.8 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.45MShares$36.7 Million0.63% of portfolio
About Kura Oncology, Inc.
- Ticker KURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,893,000
- Market Cap $552M
- Description
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...